Synthesis And Biological Evaluation of Chalcone linked Structural Modified Benzothizaole-imidazopyridine Derivatives as Anticancer agents

Abstract We have synthesized a new series of chalcone based benzothizaole-imidazopyridine (10a-j) derivatives and tested for their anticancer propertiestowards human PC3 (prostate cancer), DU-145 (Prostate cancer), A549 (lung cancer) and MCF-7 (breast cancer) cancer cell lines, and compared with standard reference of etoposide. These tested compounds displayed excellent to moderate activities on four cell lines. The compounds showed IC50 values range from 0.01±0.003µM to 19.5±6.31µM, as well as standard showed values range from 1.97 ± 0.45µM to 3.08 ± 0.135µM, respectively. Among all, these compounds 10a, 10b, 10h and 10i exhibited more potent activities than with etoposide. Exclusively, compound 10a displayed most promising activity to compare with 10b, 10h and 10i.